Overview
ENGN market data
Price History
ENGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.29 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.40 – $12.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $126.9 · P/B 2.20.
Company news
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard GlickmanBenzinga · Jul 16, 2026, 12:12 PM
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For ThursdayBenzinga · Jun 18, 2026, 12:15 PM
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For TuesdayBenzinga · Jun 16, 2026, 12:30 PM
EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202Benzinga · Jun 15, 2026, 1:30 PM
enGene Holdings Q2 EPS $(0.43) Beats $(0.47) EstimateBenzinga · Jun 15, 2026, 1:15 PM